CoChat

Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study

Suppes, Trisha, Silva, Robert, Cucchiaro, Josephine, Mao, Yongcai, Targum, Steven, Streicher, Caroline, Pikalov, Andrei, Loebel, Antony · 2016 · American Journal of Psychiatry

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Accumulating evidence indicates that manic symptoms below the threshold for hypomania (mixed features) are common in individuals with major depressive disorder. This form of depression is often severe and is associated with an increased risk for recurrence, suicide attempts, substance abuse, and functional disability. This study evaluated the efficacy and safety of lurasidone in major depressive disorder with mixed features. METHODS: Patients meeting DSM-IV-TR criteria for major depressive disorder who presented with two or three protocol-defined manic symptoms were randomly assigned to 6 weeks of double-blind treatment with either lurasidone at 20-60 mg/day (N=109) or placebo (N=100). Changes from baseline in Montgomery-Åsberg Depression Rating Scale score (MADRS; primary outcome measure) and Clinical Global Impressions severity subscale score (CGI-S; key secondary outcome measure) were evaluated using a mixed model for repeated-measures analysis. RESULTS: Lurasidone significantly improved depressive symptoms and overall illness severity, assessed by least squares mean change at week 6 in the MADRS and CGI-S scores: -20.5 compared with -13.0 (effect size, 0.80) and -1.8 compared with -1.2 (effect size, 0.60), respectively. Significant improvement in manic symptoms, assessed by the Young Mania Rating Scale, was also observed, in addition to other secondary efficacy endpoints. Rates of discontinuation due to adverse events were low. The most common adverse events were nausea (6.4% and 2.0% in the lurasidone and placebo groups, respectively) and somnolence (5.5% and 1.0%). CONCLUSIONS: Lurasidone was effective and well tolerated in this study involving patients with major depressive disorder associated with subthreshold hypomanic symptoms (mixed features).

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2015.15060770

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 39 references

Research works printed but not linked: 2

  1. First MB, 2007, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT)
  2. Clayton AH, 1997, Psychopharmacol Bull, 33, 731

Cited by

See all 334

Metadata

Authors
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A.
Affiliations
VA Palo Alto Health Care System (US)
Venue
American Journal of Psychiatry
Published
2016-04-01
Volume
173
Issue
4
Pages
400-407
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2113560690
Cited by
322
References
39
Citations by year
2026: 11 · 2025: 14 · 2024: 13 · 2023: 14 · 2022: 8 · 2021: 17 · 2020: 174 · 2019: 18 · 2018: 16 · 2017: 19 · 2016: 17
FWCI
12.73
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
lurasidone, major depressive disorder, mixed features, atypical depression, antidepressant efficacy, drug safety, nausea, sleepiness, Young Mania Rating Scale
MeSH terms
Lurasidone Hydrochloride, Adult, Bipolar Disorder, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Antipsychotic Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1176/appi.ajp.2015.15060770
The paper
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A. (2016). Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15060770

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.